Abbott Medical Devices
683
37
75
464
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
13.9%
95 terminated/withdrawn out of 683 trials
83.0%
-3.5% vs industry average
9%
64 trials in Phase 3/4
61%
283 of 464 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (683)
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Role: lead
Portico Next Generation Approval Study
Role: lead
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Role: lead
Abbott Medical - VERITAS Study
Role: lead
Agilis RF TSP Early Feasibility Study
Role: lead
ViewFlex X ICE First-in-Human Study
Role: lead
A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:
Role: lead
Amplatzer PFO Occluder Post-marketing Surveillance Study
Role: lead
Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation
Role: lead
PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)
Role: collaborator
Aveir DR i2i Study
Role: lead
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
Role: lead
BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF
Role: lead
Navitor Japan Study
Role: lead
Aveir VR Real-World Evidence Post-Approval Study
Role: lead
The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System
Role: lead
Aveir DR Real-World Evidence Post-Approval Study
Role: lead
An Observational Real-world Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip™ Device (bRIGHT)
Role: lead
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Role: lead
CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
Role: lead